Third French Congress on Mesothelioma

Our plain-English summary of Third French Congress on Mesothelioma (Pleura and Peritoneum, 2026).

The study

• Journal: Pleura and Peritoneum
• Published: 2026;11(2):89-98
• Read it: PubMed · Publisher · Free full text

In plain English

This document was a set of 11 short abstracts from the Third French Congress on Mesothelioma, held in Lyon on April 1 to 2, 2026, printed as the authors supplied them. It was not a single study. The abstracts covered laboratory work on possible treatments for pleural mesothelioma, an ongoing trial combining photodynamic therapy with nivolumab, and talks on peritoneal mesothelioma care in France. None studied asbestos exposure, though some noted in their background that pleural mesothelioma is linked to asbestos. One abstract used tumor samples from the IFCT-MAPS2 trial (34 patients given nivolumab alone, 38 given nivolumab plus ipilimumab). Among patients given nivolumab alone, those with high S-scores, a measure of the sarcomatoid component, had shorter survival than those with low S-scores (RR 4.0, 1.7 to 9.5). Among those given the combination, the authors reported that no survival difference was observed between high- and low-S-score patients (RR 0.6, 0.3 to 1.3). Another abstract reported that the RENAPE network cut median treatment delays from 4.73 to 2.35 months and built a registry of over 5,150 cases.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Collection of 11 congress abstracts (laboratory studies, analyses of trial samples, an ongoing clinical trial, network and registry reports, and one review), not a single study
• Who was studied: Varies by abstract: cell lines, tumor samples, patients in the IFCT-MAPS2 trial (34 on nivolumab alone, 38 on nivolumab plus ipilimumab), and French peritoneal cancer registry cases; presented in Lyon, April 1 to 2, 2026
• Exposure: No abstract studied asbestos exposure. Some state in their background that pleural mesothelioma is linked to or mainly caused by asbestos exposure.
• Main results:
  • IFCT-MAPS2 abstract: among patients given nivolumab alone, those with high S-scores had shorter survival than those with low S-scores (RR 4.0 [1.7 - 9.5]). Among patients given combination therapy, no difference was observed (RR 0.6 [0.3 - 1.3]).
  • RENAPE network abstract: median treatment delays for rare peritoneal cancers fell from 4.73 months to 2.35 months.
  • RENAPE network abstract: the national registry held over 5,150 cases.
  • Peritoneal mesothelioma surgery abstract: in 288 selected epithelioid mesotheliomas from the RENAPE registry treated with CC-0 or CC-1 CRS-HIPEC, estimated 10-year recurrence-free survival was 28%, with a median of 37 months.
  • Review abstract on systemic treatment of peritoneal mesothelioma: first-line platinum-pemetrexed chemotherapy gave a median overall survival of 38.9 months (n=139).
  • TEAD abstract (pleural mesothelioma cell lines): effective inhibition required targeting TEAD1, TEAD3 and TEAD4 together.
  • IMPALA trial abstract: about 75% of planned patients had been enrolled. No outcome results were reported.
• The authors' conclusion: There is no overall conclusion. Each abstract states its own conclusion about its own work.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma.

Related studies

• The role of surgical cytoreduction in the treatment of malignant pleural mesothelioma: meeting summary of the International Mesothelioma Interest Group Congress, September 11-14, 2012, Boston, Mass — V. Rusch, E.H. Baldini, et al. (2013)
• ERS International Congress 2023: highlights from the Thoracic Oncology Assembly — M.J. Catarata, A.W. Creamer, et al. (2024)
• ERS International Congress 2021: highlights from the Thoracic Surgery and Lung Transplantation Assembly — S. Bos, S. Ricciardi, et al. (2022)
• Congress considers asbestos indemnity bill — R.J. Smith (1979)
• Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial — M. Maio, A. Scherpereel, et al. (2017)
• Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma — M.G. Zauderer, S.L. Kass, et al. (2014)

Browse more research in Pleura and Peritoneum, or return to medical research.